Showing 621 - 640 results of 133,827 for search '(( 5 ((((we decrease) OR (nn decrease))) OR (a decrease)) ) OR ( a d decrease ))', query time: 2.01s Refine Results
  1. 621
  2. 622
  3. 623
  4. 624
  5. 625
  6. 626
  7. 627
  8. 628
  9. 629

    Nimodipine does not decrease markers of neuritic dystrophy in 5XFAD transgenic mice. by Katherine R. Sadleir (12035242)

    Published 2022
    “…<p><b>(</b>A and F) Representative immunoblots of hippocampal (A) and cortical (F) lysates of non-transgenic and 5XFAD mice treated with vehicle or nimodipine. …”
  10. 630
  11. 631
  12. 632

    Zileuton, 5-Lipoxygenase Inhibitor, Acts as a Chemopreventive Agent in Intestinal Polyposis, by Modulating Polyp and Systemic Inflammation by Elias Gounaris (52393)

    Published 2015
    “…Here we report that Zileuton, a specific 5-LO inhibitor, can prevent polyp formation by efficiently reducing the tumor-associated and systemic inflammation in APC<sup>Δ468</sup> mice.…”
  13. 633
  14. 634

    Dexamethasone decreases CRTC1 and CRTC2 nuclear localization. by Jill A. Rahnert (2872766)

    Published 2016
    “…<p>Treatment of L6 myotubes with Dex (100nM, 48hrs) decreased (A) total CRTC1 (p = 0.004 and CRTC2 protein (p = 0.0007). n = 9/treatment from 3 experiments. …”
  15. 635

    Dexamethasone decreases PGC-1α protein expression and transcription. by Jill A. Rahnert (2872766)

    Published 2016
    “…<p>(A) Treatment of L6 myotubes with Dex (100nM, 48hrs) decreased PGC-1α protein expression (p = 0.01). n = 3/treatment from 3 experiments. …”
  16. 636
  17. 637
  18. 638
  19. 639
  20. 640

    Decreased proliferation after overexpression of T-STAR in five breast cancer cell lines. by Sandra Sernbo (438551)

    Published 2013
    “…B) Increased (676%) T-STAR protein level (WB) compared to GFP (16%) and wt (100%) control cells in the MDA-MB-231 cell line after overexpression. C) A decrease in proliferation could be detected at 48 h after overexpressing T-STAR using thymidine incorporation and D) after 48 h (PMC42, L56Br-C1 and T47D) or 72 h (JIMT-1 and MDA-MB-231) upon assessment of enzymatic activity (WST-1 assay). …”